The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

This would reverse progress toward curbing drug shortages. AstraZeneca scrapped plans to invest $558.3 million in its vaccine ...

IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...

Nitrous oxide is widely available as long as everyone pretends it’s being used for whipped cream. An industry has arisen to ...

With pharmaceutical companies heavily investing in R&D and precision medicine, the demand for high-quality specialty APIs is ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Neither regulators nor police have attacked illegal production, promotion, and sale with sufficient vigor, perhaps because ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...